Rex Bright Net Worth

Rex Bright biography

Rex Bright serves as Director of the Company. He served as a director of Foamix from September 2014 until the Closing Date. Mr. Bright is currently retired, but previously held chief executive officer positions in the health care industry for over 20 years. Mr. Bright was the co-founder and Chief Executive Officer of SkinMedica, a specialty pharmaceutical business that was later acquired by Allergan in 2012. Mr. Bright also held executive positions for Johnson & Johnson and GlaxoSmithKline. Mr. Bright previously served as a director of RestorGenex Corporation until 2016 when the company was acquired. Mr. Bright holds a B.A. in Business Administration and Marketing from Drury University.

How old is Rex Bright?

Rex Bright is 79, he's been the Director of Menlo Therapeutics since 2020. There are no older and 9 younger executives at Menlo Therapeutics.

What's Rex Bright's mailing address?

Rex's mailing address filed with the SEC is Rehovot, Israel.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr e Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer